Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TriReme Medical, a privately held medical device company, has received CE Marking and commercialization approval in Europe for the Antares coronary stent system, a main vessel stent system specially designed for use at or near coronary bifurcations.
Subscribe to our email newsletter
Combining a low profile stent with a proprietary delivery system, the Antares system provides a unique set of solutions to the challenges of bifurcation stenting, the company said.
It can be delivered and deployed in a single step while maintaining access to the side branch and scaffolding the ostium, or the origin of the side branch. As a result, the cardiologist has greater flexibility of treatment options, with the freedom to deploy a second stent in the side branch when additional support is necessary, added TriReme Medical.
Eitan Konstantino, president and CEO of TriReme Medical, said: “We are very pleased to achieve this significant milestone that allows commercialization of our Antares stent system in Europe. We believe that the Antares stent system represents a breakthrough in the treatment of patients suffering from coronary artery disease at or near bifurcations.”